oral glp-1 agonist approved List of and pending medications Oral Semaglutide Approved to Reduce

The present review ultimately weighs early concerns against increasingly consistent evidence that GLP-1 RA use does not raise overall cancer risk, clarifies that breast cancer risk appears neutral, and further highlights key mechanisms, such as the reduction of hyperinsulinemia and immune-microenvironment modulation, through which these drugs may improve rather than exacerbate malignancy outcomes

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G

Emerging multi-agonists such as retatrutide (GLP-1/GIP/glucagon triple agonist) and PTT-A (novel unimolecular peptide tetra-agonist targeting GLP-1, GIP, glucagon and amylin receptors) further expand this concept

Healthcare professionals work closely with patients to combine this treatment with tailored lifestyle modifications, including diet and exercise, to maximize weight loss results

W., Mcdonald D., et al

Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats